Affymetrix Bets Branched DNA Will Drive Growth in Expression Market

Affymetrix retains a majority share of the global array-based gene-expression market and believes its branched DNA-based QuantiGene kits, on board since its 2008 acquisition of Panomics, will spur future growth and provide it a platform to challenge RT-PCR.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.